APC
Jhajjar, India
APC
Jhajjar, India

Time filter

Source Type

Schapira A.H.V.,University College London | Fox S.H.,University of Toronto | Hauser R.A.,University of South Florida | Jankovic J.,Baylor College of Medicine | And 6 more authors.
JAMA Neurology | Year: 2017

IMPORTANCE Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias. Management of such complications continues to be a significant challenge. OBJECTIVE To investigate the efficacy and safety of safinamide (an oral aminoamide derivative with dopaminergic and nondopaminergic actions) in levodopa-treated patients with motor fluctuations. DESIGN, SETTING, AND PARTICIPANTS From March 5, 2009, through February 23, 2012, patients from academic PD care centers were randomized (1:1 ratio) to receive double-blind adjunctive safinamide or placebo for 24 weeks. All patients had idiopathic PD with "off" time (time when medication effect has worn off and parkinsonian features, including bradykinesia and rigidity, return) of greater than 1.5 hours per day (excluding morning akinesia). Their pharmacotherapy included oral levodopa plus benserazide or carbidopa in a regimen that had been stable for 4 weeks or longer. During screening, each patient's regimen was optimized to minimize motor fluctuations. Study eligibility required that after 4 weeks of optimized treatment, the patients still have more than 1.5 hours per day of off time. Adverse events caused the premature study discontinuation of 12 individuals (4.4%) in the safinamide group and 10 individuals (3.6%) in the placebo group. INTERVENTIONS Patients took safinamide or placebo as 1 tablet daily with breakfast. If no tolerability issues arose by day 14, the starting dose, 50mg, was increased to 100mg. MAIN OUTCOMES AND MEASURES The prespecified primary outcomewas each treatment group's mean change from baseline to week 24 (or last "on" treatment value) in daily "on" time (relief of parkinsonian motor features) without troublesome dyskinesia, as assessed from diary data. RESULTS At 119 centers, 549 patients were randomized (mean [SD] age, 61.9 [9.0] years; 334 male [60.8%] and 371 white [67.6%]): 274 to safinamide and 275 to placebo. Among them, 245 (89.4%) receiving safinamide and 241 (87.6%) receiving placebo completed the study. Mean (SD) change in daily on time without troublesome dyskinesia was +1.42 (2.80) hours for safinamide, from a baseline of 9.30 (2.41) hours, vs +0.57 (2.47) hours for placebo, from a baseline of 9.06 (2.50) hours (least-squares mean difference, 0.96 hour; 95%CI, 0.56-1.37 hours; P < .001, analysis of covariance). The most frequently reported adverse event was dyskinesia (in 40 [14.6%] vs 15 [5.5%] and as a severe event in 5 [1.8%] vs 1 [0.4%]). CONCLUSIONS AND RELEVANCE The outcomes of this trial support safinamide as an effective adjunct to levodopa in patients with PD and motor fluctuations to improve on time without troublesome dyskinesia and reduce wearing off. © 2017 American Medical Association.


News Article | June 1, 2017
Site: www.marketwired.com

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 1, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC)(FRANKFURT:0E8) is pleased to announce that it will conduct a rights offering to raise gross proceeds of up to $1,900,281 (the "Rights Offering"). Under the Rights Offering, the Company will be offering transferable rights (the "Rights") to holders of its common shares (the "Common Shares") resident in Canada at the close of business on June 7, 2017 (the "Record Date"), on the basis of one Right for each Common Share held. Four Rights will entitle the holder to subscribe for one unit of the Company (a "Unit") at a subscription price of $0.06 per Unit, which represents a discount to the closing price of the Common Shares on the TSX Venture Exchange (the "Exchange") on May 31, 2017. No fractional Units will be issued. Each Unit will consist of one Common Share and one-half of one common share purchase warrant, with each whole warrant exercisable into one Common Share for a period of 12 months following the closing of the Rights Offering (the "Closing Date") at a price of $0.10 per Common Share. The Rights will expire at 5:00 p.m. (Toronto time) on July 5, 2017 (the "Expiry Time"), after which time unexercised Rights will be void and of no value. Shareholders who fully exercise their Rights will be entitled to subscribe for additional Units, if available as a result of unexercised Rights prior to the Expiry Time, subject to certain limitations set out in the rights offering circular in respect of the Rights Offering (the "Circular"). Details of the Rights Offering will be set out in the rights offering notice (the "Notice") and Circular which will be available under APC's profile on SEDAR at www.sedar.com. The Notice and accompanying rights certificate (the "Rights Certificates") will be mailed to each eligible shareholder of the Company as at the Record Date. Registered shareholders who wish to exercise their Rights must forward the completed Rights Certificates, together with the applicable funds, to the rights agent, Computershare Investor Services Inc., on or before the Expiry Time. Shareholders who own their Common Shares through an intermediary, such as a bank, trust company, securities dealer or broker, will receive materials and instructions from their intermediary. Rights delivered to brokers, dealers or other intermediaries will not be delivered by those intermediaries to beneficial shareholders who are residents in a jurisdiction outside of Canada. The Company currently has 126,685,418 Common Shares outstanding. Assuming all the Rights issued under the Rights Offering are validly exercised, the Rights Offering will raise gross proceeds of approximately $1,900,281, the net proceeds of which will be used for debt repayment as well as working capital. The Closing Date is expected to occur on or about July 10, 2017. Any person who will own or control (beneficially or as nominee) more than 10 percent of the outstanding common shares of APC at closing of the Rights Offering must file a Personal Information Form ("PIF") with the Exchange and the Rights Offering will only close in escrow with respect of such person until the Exchange has notified the Company that the results of the review of the relevant PIFs are satisfactory. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United State3s or to, or for the account of benefit of, "U.S. persons", as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available. Advanced Proteome Therapeutics Corporation (APC) is advancing a site-specific protein modification technology platform to enable the development of superior protein therapeutics. Using this technology, APC has generated numerous and diverse modifications of annexin proteins with superior binding and stability properties, which are amenable to further labeling and conjugation for use in therapeutic applications. APC is now vigorously applying its technologies to achieve the site-specific labeling of therapeutic antibodies and provide the next generation of antibody-drug conjugates. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategies, plans or intentions. In particular, this news release contains forward-looking statements including, but not limited to, statements regarding the timing of, and other procedural matters associated with, the Rights Offering, and the use of proceeds from the Rights Offering. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 11, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC)(FRANKFURT:0E8) is pleased to report that it has completed its previously announced rights offering (the "Rights Offering"). Under the Rights Offering, on July 10, 2017, 7,136,216 units of the Corporation (the "Units") were distributed at a price of $0.06 per Unit for gross proceeds to the Corporation of $428,172.96. Each Unit consists of one common share of the Corporation (a "Common Share") and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"), with each Warrant entitling its holder to purchase one additional Common Share at a price of $0.10 per Common Share until July 10, 2018. Upon closing of the Rights Offering, there are 133,821,634 Common Shares outstanding and 21,786,773 Common Shares reserved for issuance, including 11,961,773 common share purchase warrants (3,568,108 of which were issued pursuant to the Rights Offering). The Corporation intends to use the net proceeds of which will be used for debt repayment as well as working capital. To the knowledge of the Corporation, after reasonable inquiry, directors, officers and other insiders of the Corporation exercised their basic subscription privileges to acquire an aggregate of 6,250 Units under the Rights Offering, and additional subscription privileges to acquire an aggregate of 83,333 Units under the Rights Offering, representing total subscription proceeds of approximately $5,374.98. To the knowledge of the Corporation, after reasonable inquiry, no person that was not an insider became an insider of the Corporation as a result of the Rights Offering. The Corporation will pay solicitation fees in the aggregate amount of $16,701.52, representing $0.0026 for each Unit subscribed for, to members of Investment Industry Regulatory Organization of Canada (IIROC) which exercised rights on behalf of their clients. Advanced Proteome Therapeutics Corporation (APC) is advancing a site-specific protein modification technology platform to enable the development of superior protein therapeutics. Using this technology, APC has generated numerous and diverse modifications of annexin proteins with superior binding and stability properties, which are amenable to further labeling and conjugation for use in therapeutic applications. APC is now vigorously applying its technologies to achieve the site-specific labeling of therapeutic antibodies and provide the next generation of antibody-drug conjugates. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategies, plans or intentions. In particular, this news release contains forward-looking statements including, but not limited to, statements regarding the use of proceeds from the Rights Offering. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


VANCOUVER, BC--(Marketwired - November 29, 2016) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) ( : 0E8) is pleased to announce that it has invented a measurable basis for evaluating antibody labeling that provides key information on the pattern of labeling. The technology provides a means of sorting labeling entities according to the degree of selective labeling resulting from modification of a target antibody for conjugation. The methodology produces a rank order of candidate antibodies carrying antibody connectors for linkage to payloads such as drugs or toxins which should aid decision-making in ADC development. Immense growth is expected for the therapeutic antibody market which is estimated to reach nearly $125 Billion USD by the year 2020 (The therapeutic monoclonal antibody market: Ecker et al. MAbs 2015, Volume 7, ppgs 9-14.). This invention was developed to fulfil the Company's recently announced partnering initiatives with Wilex AG's subsidiary, Heidelberg Pharma GmbH and the Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto. The method has been applied to measurements of the selectivity pattern that emerges from APC's experimental conditions for labeling commercially marketed antibody targets. Despite being prerequisites for a reliable assessment of performance of labeling technology, quantitative methods for the rapid determination of the purity of antibody-drug conjugates, and an analysis of the labeling pattern which produces them, have been lacking. APC's approach to impacting the field of antibody-drug conjugates is to design a labeling entity that places a handle on the antibody to which virtually any payload such as a drug or toxin can be attached. Since the Company is targeting "universal" sites on antibodies, the type that all IgG antibodies possess, it is important to emphasize that our approach could ultimately enable attaching drugs or toxins to any target antibody selectively, for which quantitative measurements are essential. (IgGs are the principal antibody carriers of ADCs.) Apropos of the above, APC is focusing on enabling technology, designed to link antibodies to drugs or toxins to produce pure and homogeneous antibody-drug conjugates. The field of antibody-drug conjugates affords numerous opportunities for improving the properties of therapeutic antibodies, but reliable methods for site-specifically attaching drugs or toxins to antibodies to give ADCs of high purity are needed to avoid the heterogeneity that currently limits applications of ADCs. The number of therapeutic antibodies and the companies producing them are legion, and growing, but comparatively few companies have capabilities for chemical modification of such antibodies aimed at producing "kinder and gentler" agents than classical chemotherapeutics. Advanced Proteome Therapeutics Corporation (APC) is advancing a site-specific protein modification technology platform to enable the development of superior protein therapeutics. Using this technology, APC has generated numerous and diverse modifications of annexin proteins with superior binding and stability properties, which are amenable to further labeling and conjugation for use in therapeutic applications. APC is now vigorously applying its technologies to achieve the site-specific labeling of therapeutic antibodies and provide the next generation of antibody-drug conjugates. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.


Stocchi F.,IRCCS San Raffaele | Borgohain R.,Nizam's Institute of Medical Sciences | Onofrj M.,University of Chieti Pescara | Schapira A.H.,University College London | And 4 more authors.
Movement Disorders | Year: 2012

Safinamide is an α-aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add-on to dopamine agonist (DA) therapy in early-stage PD. In this 24-week, double-blind study, patients with early PD receiving a stable dose of a single DA were randomized to once-daily safinamide 100 mg, safinamide 200 mg, or placebo. The primary efficacy variable was UPDRS part III (motor examination) total score. Analysis was hierarchical: 200 mg of safinamide versus placebo was tested first; the success of safinamide 100 mg versus placebo was contingent on this. Two hundred sixty-nine patients received safinamide 100 mg (n = 90), safinamide 200 mg (n = 89), or placebo (n = 90); 70, 81, and 81 patients, respectively, completed the study. Mean improvements from baseline to week 24 in UPDRS III total scores were -3.90 for safinamide 200 mg, -6.0 for safinamide 100 mg and -3.60 for placebo. The difference between safinamide 200 mg and placebo was not significant [point estimate: -0.4; 95% confidence interval (CI): -2.3-1.4; P = 0.6504]. Although the difference between 100 mg/day and placebo was significant (point estimate: -1.9; 95% CI: -3.7 to -0.1; P = 0.0419), these results are considered exploratory. No clinically meaningful differences from placebo were observed for any safety variables. This study did not demonstrate a significant improvement of the primary endpoint for safinamide 200 mg/day. Exploratory analysis of the primary endpoint for 100 mg/day demonstrated that the addition of safinamide to a stable dose of DA improves motor symptoms in early PD and warrants further investigation. © 2011 Movement Disorder Society.


PubMed | University of Kansas Medical Center, Innsbruck Medical University, Autonomous University of Barcelona, Baylor College of Medicine and 6 more.
Type: | Journal: JAMA neurology | Year: 2016

Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias. Management of such complications continues to be a significant challenge.To investigate the efficacy and safety of safinamide (an oral aminoamide derivative with dopaminergic and nondopaminergic actions) in levodopa-treated patients with motor fluctuations.From March 5, 2009, through February 23, 2012, patients from academic PD care centers were randomized (1:1 ratio) to receive double-blind adjunctive safinamide or placebo for 24 weeks. All patients had idiopathic PD with off time (time when medication effect has worn off and parkinsonian features, including bradykinesia and rigidity, return) of greater than 1.5 hours per day (excluding morning akinesia). Their pharmacotherapy included oral levodopa plus benserazide or carbidopa in a regimen that had been stable for 4 weeks or longer. During screening, each patients regimen was optimized to minimize motor fluctuations. Study eligibility required that after 4 weeks of optimized treatment, the patients still have more than 1.5 hours per day of off time. Adverse events caused the premature study discontinuation of 12 individuals (4.4%) in the safinamide group and 10 individuals (3.6%) in the placebo group.Patients took safinamide or placebo as 1 tablet daily with breakfast. If no tolerability issues arose by day 14, the starting dose, 50 mg, was increased to 100 mg.The prespecified primary outcome was each treatment groups mean change from baseline to week 24 (or last on treatment value) in daily on time (relief of parkinsonian motor features) without troublesome dyskinesia, as assessed from diary data.At 119 centers, 549 patients were randomized (mean [SD] age, 61.9 [9.0] years; 334 male [60.8%] and 371 white [67.6%]): 274 to safinamide and 275 to placebo. Among them, 245 (89.4%) receiving safinamide and 241 (87.6%) receiving placebo completed the study. Mean (SD) change in daily on time without troublesome dyskinesia was +1.42 (2.80) hours for safinamide, from a baseline of 9.30 (2.41) hours, vs +0.57 (2.47) hours for placebo, from a baseline of 9.06 (2.50) hours (least-squares mean difference, 0.96 hour; 95% CI, 0.56-1.37 hours; P<.001, analysis of covariance). The most frequently reported adverse event was dyskinesia (in 40 [14.6%] vs 15 [5.5%] and as a severe event in 5 [1.8%] vs 1 [0.4%]).The outcomes of this trial support safinamide as an effective adjunct to levodopa in patients with PD and motor fluctuations to improve on time without troublesome dyskinesia and reduce wearing off.clinicaltrials.gov Identifier NCT00627640.


Cai Z.-Y.,International School for Advanced Studies | Cai Z.-Y.,Xiamen University | Lapi A.,International School for Advanced Studies | Lapi A.,University of Rome Tor Vergata | And 10 more authors.
Astrophysical Journal | Year: 2013

We present a comprehensive investigation of the cosmological evolution of the luminosity function of galaxies and active galactic nuclei (AGNs) in the infrared (IR). Based on the observed dichotomy in the ages of stellar populations of early-type galaxies on one side and late-type galaxies on the other, the model interprets the epoch-dependent luminosity functions at z ≥ 1.5 using a physical approach for the evolution of proto-spheroidal galaxies and of the associated AGNs, while IR galaxies at z < 1.5 are interpreted as being mostly late-type "cold" (normal) and "warm" (starburst) galaxies. As for proto-spheroids, in addition to the epoch-dependent luminosity functions of stellar and AGN components separately, we have worked out, for the first time, the evolving luminosity functions of these objects as a whole (stellar plus AGN component), taking into account in a self-consistent way the variation with galactic age of the global spectral energy distribution. The model provides a physical explanation for the observed positive evolution of both galaxies and AGNs up to z ≃ 2.5 and for the negative evolution at higher redshifts, for the sharp transition from Euclidean to extremely steep counts at (sub-)millimeter wavelengths, as well as the (sub-)millimeter counts of strongly lensed galaxies that are hard to account for by alternative, physical or phenomenological, approaches. The evolution of late-type galaxies and z < 1.5 AGNs is described using a parametric phenomenological approach. The modeled AGN contributions to the counts and to the cosmic infrared background (CIB) are always sub-dominant. They are maximal at mid-IR wavelengths: the contribution to the 15 and 24 μm counts reaches 20% above 10 and 2 mJy, respectively, while the contributions to the CIB are of 8.6% and of 8.1% at 15 μm and 24 μm, respectively. The model provides a good fit to the multi-wavelength (from the mid-IR to millimeter waves) data on luminosity functions at different redshifts and on number counts (both global and per redshift slices). A prediction of the present model, useful to test it, is a systematic variation with wavelength of the populations dominating the counts and the contributions to the CIB intensity. This implies a specific trend for cross-wavelength CIB power spectra, which is found to be in good agreement with the data. © 2013. The American Astronomical Society. All rights reserved.


Semikoz D.,APC
2009 CERN-Latin-American School of High-Energy Physics, CLASHEP 2009 - Proceedings | Year: 2010

In these three lectures I discuss the present status of high-energy astroparticle physics including Ultra-High-Energy Cosmic Rays (UHECR), high-energy gamma rays, and neutrinos. The first lecture is devoted to ultra-high-energy cosmic rays. After a brief introduction to UHECR I discuss the acceleration of charged particles to highest energies in the astrophysical objects, their propagation in the intergalactic space, recent observational results by the Auger and HiRes experiments, anisotropies of UHECR arrival directions, and secondary gamma rays produced by UHECR. In the second lecture I review recent results on TeV gamma rays. After a short introduction to detection techniques, I discuss recent exciting results of the H.E.S.S., MAGIC, and Milagro experiments on the point-like and diffuse sources of TeV gamma rays. A special section is devoted to the detection of extragalactic magnetic fields with TeV gammaray measurements. Finally, in the third lecture I discuss Ultra-High-Energy (UHE) neutrinos. I review three different UHE neutrino detection techniques and show the present status of searches for diffuse neutrino flux and point sources of neutrinos.


Rasmussen N.,APC
EngineerIT | Year: 2011

Neil Rasmussen, APC, informs about terms, such as power factor, crest factor, and surge factor, which refer to completely different and unrelated phenomena. Power factor is a quantity which has important implications when implementing a UPS system and power distribution equipment. Power is a measure of the delivery rate of energy and in direct current (DC) electrical circuits is expressed as the mathematical product of volts and amps. Crest factor is the ratio between the instantaneous peak current required by the load and the root mean square (RMS) current. Most common electrical appliances exhibit a crest factor of 1,4, while computers and IT equipment with power factor corrected power supplies exhibit a crest factor of 1,4. Surge factor relates to the momentary overload capacity of the UPS and is a measure of the ability of the UPS to startup loads, which temporarily require extra power when they start-up.


Binetruy P.,APC | Bohe A.,APC | Hertog T.,APC | Steer D.A.,APC
Physical Review D - Particles, Fields, Gravitation and Cosmology | Year: 2010

Junctions on cosmic string loops give rise to the proliferation of sharp kinks. We study the effect of this proliferation on the gravitational wave (GW) signals emitted from string networks with junctions, assuming a scaling solution. We calculate the rate of occurrence and the distribution in amplitude of the GW bursts emitted at cusps and kinks in the frequency bands of LIGO/VIRGO and LISA as a function of the string tension, the number of sharp kinks on loops with junctions, and the fraction of loops in the cosmological network which have junctions. Combining our results with current observational constraints, we find that pulsar data rule out a significant number of kinks on loops for strings with tensions Gμ10⊃-12. By contrast, for smaller tensions current observations allow for a large number of kinks on loops. If this is the case, the incoherent superposition of small bursts emitted at kink-kink encounters leads to an enhanced GW background that hides the strong individual bursts from kinks and cusps. © 2010 The American Physical Society.

Loading APC collaborators
Loading APC collaborators